Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade
B. M. Foda, S. A. Misek, K. A. Gallo, R. R. Neubig
This study shows that inhibiting the Rho/MRTF pathway with CCG-257081 enhances the effectiveness of PD1/PDL1 blockade in BRAF-resistant melanoma.
bioRxiv · Dec 20, 2023Cancer Biology